ClearPoint Neuro Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

ClearPoint NeuroDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -31.5% zurückgegangen, während in der Branche Medical Equipment die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 20.5% pro Jahr.

Wichtige Informationen

-31.5%

Wachstumsrate der Gewinne

-16.3%

EPS-Wachstumsrate

Medical Equipment Wachstum der Industrie8.9%
Wachstumsrate der Einnahmen20.5%
Eigenkapitalrendite-59.6%
Netto-Marge-78.8%
Letzte Ertragsaktualisierung31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

ClearPoint Neuro: Macro-Induced Multiple Compression

Apr 25

Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?

Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report

Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Jan 04
Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Dec 06
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Nov 06
Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Aug 18
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Apr 17
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump

Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

Jan 03
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?

ClearPoint Neuro: Continuous Great Execution

Sep 19

ClearPoint Neuro: Picks & Shovels Galore

Aug 19

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Aug 18
ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro:  A 'Picks And Shovels' Biotech Company

Jul 25

ClearPoint Neuro: Continuous Execution Despite Covid Headwind

May 20

Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

Apr 25
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?

ClearPoint Neuro: A Strong Recovery Play Once COVID Subsides

Mar 18

ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

Jan 19
ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?

ClearPoint Neuro: Underlying Growth Potential Concealed By COVID

Jan 14

ClearPoint Neuro: Becoming The Neurosurgical Platform Of Choice

Oct 01

ClearPoint Neuro: Path To Being The Neurological Navigation Platform Company

Aug 06

Health Check: How Prudently Does ClearPoint Neuro (NASDAQ:CLPT) Use Debt?

Jul 19
Health Check: How Prudently Does ClearPoint Neuro (NASDAQ:CLPT) Use Debt?

Clearpoint Neuro (CLPT) Investor Presentation - Slideshow

May 28

Why We Think Shareholders May Be Considering Bumping Up ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO Compensation

May 27
Why We Think Shareholders May Be Considering Bumping Up ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO Compensation

US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results

May 13
US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results

Aufschlüsselung der Einnahmen und Ausgaben

Wie ClearPoint Neuro Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

NasdaqCM:CLPT Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
31 Mar 2426-212511
31 Dec 2324-222412
30 Sep 2322-222312
30 Jun 2322-212212
31 Mar 2321-182111
31 Dec 2221-161911
30 Sep 2220-161811
30 Jun 2219-161811
31 Mar 2217-161611
31 Dec 2116-14159
30 Sep 2116-12148
30 Jun 2115-9137
31 Mar 2114-7115
31 Dec 2013-7115
30 Sep 2012-7104
30 Jun 2012-6103
31 Mar 2012-6103
31 Dec 1911-693
30 Sep 1910-583
30 Jun 199-582
31 Mar 198-682
31 Dec 187-682
30 Sep 187-782
30 Jun 187-782
31 Mar 187-783
31 Dec 177-783
30 Sep 177-783
30 Jun 177-883
31 Mar 176-883
31 Dec 166-883
30 Sep 166-883
30 Jun 165-582
31 Mar 165-782
31 Dec 155-882
30 Sep 154-992
30 Jun 153-1393
31 Mar 154-1193
31 Dec 144-583
30 Sep 144-483
30 Jun 144-473
31 Mar 143-473
31 Dec 134-773
30 Sep 135-463

Qualität der Erträge: CLPT ist derzeit unrentabel.

Wachsende Gewinnspanne: CLPT ist derzeit unrentabel.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: CLPT ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 31.5% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von CLPT verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: CLPT ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Medical Equipment (2.4%) erschwert.


Eigenkapitalrendite

Hohe Eigenkapitalrendite: CLPT hat eine negative Eigenkapitalrendite (-59.64%), da es derzeit unrentabel ist.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren